10 September 2014

 

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Interim Results for the six months ended 30 June 2014

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces its interim results for the six months ended 30 June 2014.

 

 

Financial Highlights:
•	Group revenue up 7.5% to £29.4 million (2013 H1: £27.4 million), or 11% on a constant currency basis1
•	Adjusted2 operating margin up 70 bps to 24.5% (2013 H1: 23.8%)
•	Adjusted2 profit before tax up 18% to £7.3 million (2013 H1: £6.2 million)
	•	Profit before tax up 18% to £7.1 million (2013 H1: £6.0 million)
•	Adjusted2 diluted earnings per share up 13% to 2.92p (2013 H1: 2.59p)
	•	Diluted earnings per share up 13% to 2.82p (2013 H1: 2.49p)
•	Net cash3 increased to £10.2 million (31 December 2013: £5.3 million)
•	Interim dividend of 0.22p per share (2013 H1: 0.19p), a 15.8% increase

 

Business Highlights:
•	Good revenue growth across the major Business Units:
	○	Branded Direct up 6% to £11.6 million (2013 H1: £11.0 million) and by 8% at constant currency
	○	Branded Distributed up 18% to £4.1 million (2013 H1: £3.5 million) and by 27% at constant currency
	○	OEM up 10% to £11.8 million (2013 H1: £10.7 million) and by 13% at constant currency
	○	Bulk Materials down 14% to £1.9 million (2013 H1: £2.2 million) and down by 12% at constant currency
•	Strong performance in the US with LiquiBand® tissue adhesive range:
	○	Revenues up 64% at constant currency
	○	As at July 2014, market share by volume increased to 18% (June 2013: 17%) in the alternate site segment and 6% (June 2013: 4%) in the hospital segment
•	ActivHeal® continues to perform well in the NHS, with an 11% increase in revenues
•	Steady progress with RESORBA® brands in Germany, resulting in 5% growth at constant currency
•	Silver alginate revenues increased by 14% at constant currency to £6.8 million (2013 H1: £6.0 million)
•	Hernia Mesh Fixation device LiquiBand® Fix8™ approved in the EU at the end of May 2014 and successfully used on patients for the first time

 

 

Commenting on the results Peter Allen, Chairman of AMS, said:

 

“The first half of 2014 has seen another good performance by the Group and we are confident of meeting current market expectations for the full year.”

 

– End –

 

1    Constant currency removes the effect of currency movements by re-translating the current period’s performance at the previous period’s exchange rates

2    All items are shown before amortisation of acquired intangible assets which, in 2014 H1, were £0.2 million (2013 H1: £0.2 million) as defined in the financial review

3    Net cash is defined as cash and cash equivalents plus short term investments less financial liabilities and bank loans

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Tavistock Communications	Tel: +44 (0) 20 7920 3150
Chris Munden / Andrew Dunn / Niall Walsh
Investec Bank plc (NOMAD) & Broker	Tel: +44 (0) 20 7597 5970
Gary Clarence / Daniel Adams / Patrick Robb

 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$20 billion global wound care and wound closure market. AMS has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

 

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer (“OEM”) customers around the world, but the majority of the Group’s revenues now come from its own brands – ActivHeal^® wound care products in the UK to the NHS, LiquiBand^® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA^® sutures and haemostat products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.

 

AMS’s products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.

 

With 465 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS’s products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.

 

 

 

 

 

Chairman’s Statement

 

I am pleased to report that AMS has performed well in the first half of 2014 and that we are on track to deliver another year of good growth.

 

Revenue increased by 7.5% to £29.4 million (2013 H1: £27.4 million), representing growth of 11% at constant currency and adjusted profit before tax¹ increased by 18% to £7.3 million (2013 H1: £6.2 million). The Group continued with its strong cash generation and our net cash position has increased significantly to £10.2 million (31 December 2013: £5.3 million) as at 30 June 2014.

 

The Group’s portfolio of brands continued to perform well and the success of our partners is also driving growth in our OEM business unit.

 

Our Hernia Mesh Fixation device LiquiBand^® Fix8™ was approved for use in the EU on 29 May 2014 and is a key development for the Group as it is the first application for our medical adhesives that allows the use of LiquiBand^® within the body. This product has now been launched and the early response from users is positive.

 

The Group continues to develop new products through its Research and Development (R&D) team, building a pipeline which will support growth with our partners, distributors and our sales teams.

 

Our strong balance sheet also allows us to consider potential acquisitions that are in line with the Group’s stated strategy.  

 

Dividend

 

The Board intends to pay an interim dividend of 0.22p per share (2013 H1: 0.19p), an increase of 15.8%, on 31 October 2014 to shareholders on the register at the close of business on 3 October 2014.

 

People

 

On behalf of the Board, I would like to thank all Group employees for their continued hard work in the development of AMS as a global medical technology business, as well as our customers, suppliers, business partners and shareholders for their continued support.

 

Outlook

 

The Group continues to trade in line with current market expectations for the year ending 31 December 2014.

 

 

Peter Allen

Chairman

 

 

1    Adjusted profit before tax is adjusted for amortisation of acquired intangible assets

 

 

 

 

 

Business Review

 

Branded Direct

 

Branded Direct revenue was 6% higher at £11.6 million (2013 H1: £11.0 million) and 8% higher at constant currency.

 

ActivHeal^®

Sales of our ActivHeal^® range of wound care dressings into the NHS were 11% ahead at £2.7 million (2013 H1: £2.5 million). The ActivHeal^® proposition of delivering significant cost savings without compromising clinical outcomes or patient care continues to appeal to NHS Trusts and hence we expect good growth to continue from this brand.  

 

LiquiBand^®

UK sales of LiquiBand^® into the Accident and Emergency Room (‘A&E’) grew 12% to £1.3 million (2013 H1: £1.2 million) and sales into the Operating Room (‘OR’) increased 70% to £0.3 million (2013 H1: £0.2 million). We are pleased with the continued success of LiquiBand^® in the A&E, where we already have a market leadership position, and with the early success of our surgical sales team who are able to access the OR with our extended range of products that now includes haemostats and sutures from RESORBA^®.

 

Sales of LiquiBand^® into Germany grew by 3% to £0.7 million or 6% at constant currency. Steady growth in Germany is expected to continue.

 

RESORBA^®

Sales of RESORBA^® branded products into Germany and the Czech Republic grew by 2% to £6.8 million (2013 H1: £6.7 million), and by 5% at constant currency. Within this, sales of haemostats increased by 10% at constant currency to £1.9 million and sales of sutures and collagens into the dental market grew by 5% at constant currency to £2.0 million, whilst sales of sutures into hospitals grew 3%, reversing the decline reported in 2013 and making an encouraging start to the year.

 

In the UK, sales of RESORBA^® sutures and haemostats are increasing but still at a low level. We expect growth to build steadily as the NHS becomes more familiar with the RESORBA^® brand.

 

R&D is focusing on extending the attributes of our collagens to meet the needs of dental practitioners and oral surgeons. We are on track to launch an enhanced collagen cone in 2015, as well as making good progress in including new antibiotics in our haemostats.

 

Branded Distributed

 

Branded Distributed revenue was 18% higher at £4.1 million (2013 H1: £3.5 million) and 27% higher at constant currency.

 

LiquiBand^® in the US

Sales of LiquiBand^® to the US increased by 51% in the first half to £1.3 million (2013 H1: £0.8 million) and by 64% at constant currency, with the benefits of our increased spread of distribution partners helping us to gain better access, particularly into the hospital sector in the US market.

 

The latest data for July 2014 has our volume market share in the US hospital sector increasing to 6%, up from 4% at June 2013, while our volume market share in the US non-hospital or alternate site market is now an estimated 18%, up from 17% at June 2013. We are pleased with the progress that our partners are now making and that LiquiBand^®‘s combination of technical superiority and price competitiveness will enable us to continue to take market share from the leading brand.

 

The clinical evaluations of our 2-octyl cyanoacrylate formulation which received FDA clearance in 2013 have now been completed and we will be launching this product into the US with at least one of our existing partners in 2014 H2.

 

LiquiBand^® in the EU and ROW

Within the EU and ROW, LiquiBand^® sales through our distributors have continued to perform well and sales increased by 8% to £0.6 million (2013 H1: £0.6 million) at reported currency and by 9% at constant currency.

 

The regulatory approval process for LiquiBand^® in China is continuing although, due to changes in the regulatory pathway, approval is now expected in 2015.

 

Hernia Mesh Fixation device – LiquiBand^® Fix8™

Approval for LiquiBand^® Fix8™ for the European market was received on 29 May 2014 and the product has now been launched in both the UK and Germany. The response from surgeons has been enthusiastic and, following initial evaluations, we have already received our first orders in the UK. We have also made the product available to a few European distributors who have the sales capability to support the product. We expect to report a small level of sales in 2014 H2.

 

RESORBA^® 

Sales of RESORBA^® products to all export markets other than Russia grew by 11% at reported currency to £1.5 million (2013 H1: £1.3 million), and by 14% at constant currency. Growth was seen across several territories, with our French and Spanish distributors performing strongly. Sales into the Russian market, however, decreased 12% to £0.6 million (2013 H1: £0.7 million) at reported currency but increased by 7% at constant currency, reflecting the weakness of the Rouble.

 

Work is ongoing to gain approval to supply RESORBA^® sutures and haemostats into the US market. We have received our first approval for the sale of one type of suture for the US market and we are hopeful that the remainder of the suture range will be approved by 2015 H1, with products being launched in 2015 H2.

 

R&D is currently focusing on improving the formulations of the base monomers that go into our adhesives as well as extending the applications of tissue adhesives for internal use.

 

OEM

 

OEM revenue increased by 10% at reported currency to £11.8 million (2013 H1: £10.7 million) and by 13% at constant currency.

 

Our silver alginate ranges of dressings continue to perform well with sales increasing by 14% at reported currency and by 15% at constant currency to £6.8 million (2013 H1: £5.8 million). We continue to support our partners with regulatory matters and marketing data.

 

Sales of our foam-based dressings continued to perform well and increased 8% to £0.7 million (2013 H1: £0.6 million) while our other woundcare products also grew 23% to £3.8 million (2013 H1: £3.1 million).  

 

This business unit’s R&D is further developing our foam range to include both an antimicrobial and an atraumatic foam. Product launches are expected to be in early 2015 as regulatory approval is not expected until the end of 2014.

 

Bulk Materials

 

Bulk Materials revenue decreased by 14% at reported currency to £1.9 million (2013 H1: £2.2 million) and by 12% at constant currency.

 

The foam rollstock business is now starting to see repeat orders following the pipeline-filling that occurred in 2011, but the level of re-ordering is lower than expected. The new contracts that we signed in 2013 have been slow to grow and our bulk alginate business has been lower than expected in H1. We expect in time that our new customers for foam will develop but we expect that sales in this business unit will be flat overall in 2014.

 

In terms of R&D, this business unit continues to focus on developing new foam formulations with antimicrobials, working in conjunction with the OEM business unit. 

 

Operations

 

Operational improvements are ongoing with a continuous improvement cycle of reducing set up times, eliminating non-value added activities and increasing outputs. These incremental changes are helping to improve gross margins across the Group. We have also identified some areas where additional capital is needed to provide equipment for extra operational flexibility or to improve efficiency. This equipment, with an associated spend of approximately £1.0 million, is scheduled to be commissioned in 2014 H2. We have also been investing in improving our ERP (Enterprise Resource Planning) management and reporting systems. Following a successful launch at our Plymouth site, our new ERP system was launched in Winsford in February 2014 and is scheduled to launch in Etten Leur in the Netherlands in 2014 Q3.

 

Financial Review

 

Summary

 

Revenue increased by 7.5% to £29.4 million (2013 H1: £27.4 million). At constant currency, revenue growth would have been 11%.

 

Amortisation of acquired intangible assets was £0.2 million in the period (2013 H1: £0.2 million).

 

Comparisons with 2013 are made on a pre-amortisation of acquired intangible asset cost basis, as we believe that this provides a more relevant representation of the Group’s trading performance. To aid comparison, the Group’s adjusted income statement is summarised in Table 1 below.

 

Table 1	Six months ended 30 June 2014	Six months ended 30 June 2013
Adjusted Income Statement	£’000	£’000	Change
Revenue	29,440	27,392	7.5%
Gross profit	16,840	15,644	7.7%
Distribution costs	(381)	(324)
Administrative expenses2	(9,377)	(8,882)
Other income	142	90
Adjusted operating profit	7,224	6,528	10.7%
Net finance income/(costs)	27	(361)
Adjusted profit before tax	7,251	6,167	17.6%
Amortisation of acquired intangibles	(197)	(200)
Profit before tax	7,054	5,967	18.2%
Tax	(1,090)	(778)
Profit for the period	5,964	5,189	14.9%
Adjusted earnings per share – basic3	2.97p	2.63p	13.0%
Earnings per share – basic3	2.88p	2.53p	13.6%
Adjusted earnings per share – diluted3	2.92p	2.59p	12.6%
Earnings per share – diluted3	2.82p	2.49p	13.2%

2    Administration expenses exclude amortisation of acquired intangible assets

3    See Note 4 Earnings per share for details of calculation

 

Across the Group gross margins improved by 10 bps to 57.2% (2013 H1: 57.1%).

 

Adjusted operating profit increased by 10.7% to £7.2 million (2013 H1: £6.5 million) and the adjusted operating margin increased by 70 bps to 24.5% (2013 H1: 23.8%).

 

Adjusted diluted earnings per share increased by 12.6% to 2.92p (2013 H1: 2.59p) and diluted earnings per share increased by 13.2% to 2.82p (2013 H1: 2.49p).

 

The Group generated a profit from operating activities of £7.0 million (2013 H1: £6.3 million) and had net cash of £10.2 million at the half year end (2013 H1: net debt of £2.6 million).

 

The Group has a strong balance sheet, enabling financing of further organic growth and appropriate acquisitions.

 

Income Statement

 

The operational performance of the business units is shown in Table 2 below. The adjusted profit from operations and the adjusted operating margin are shown after excluding amortisation of acquired intangibles.

 

Table 2
Operating result by business segment
Six months ended 30 June 2014	Branded direct	Branded distributed	OEM	Bulk materials
	£’000	£’000	£’000	£’000
Revenue	11,648	4,089	11,831	2,2694
Profit from operations	3,317	702	3,194	223
Amortisation of acquired intangibles	126	61	10	–
Adjusted profit from operations5	3,443	763	3,204	223
Adjusted operating margin5	29.6%	18.7%	27.1%	9.8%
Six months ended 30 June 2013
Revenue	11,001	3,465	10,743	2,571
Profit from operations	2,906	574	2,541	518
Amortisation of acquired intangibles	125	56	19	–
Adjusted profit from operations5	3,031	630	2,560	518
Adjusted operating margin5	27.6%	18.2%	23.8%	20.1%

4    Revenue includes intersegment sales

5    Excludes amortisation of acquired intangible assets

Note: Expenses relating to non-executive Directors are not allocated to business units and are included within unallocated expenses.

 

Branded Direct

Branded Direct revenues increased by 5.9% to £11.6 million (2013 H1: £11.0 million) and by 8.0% at constant currency, with sales of ActivHeal^® and LiquiBand^® driving growth in the UK, and RESORBA^® brands supporting growth in Germany and Czech Republic. Fee income of £0.1 million was received from the licensing of Intellectual Property to third parties (2013 H1: £0.1 million).

 

Adjusted operating margin increased by 200 bps to 29.6%, due partly to a change in sales mix but mainly as a result of overhead costs remaining at a similar level compared with the prior year. R&D expense in this segment was 2.9% of revenue (2013 H1: 3.4%) on projects to develop improved collagens.

 

Branded Distributed

Branded Distributed revenues increased by 18.0% to £4.1 million (2013 H1: £3.5 million) and by 26.8% at constant currency, with sales of LiquiBand^® into the US being the main driver of growth.

 

Adjusted operating margin increased by 50 bps to 18.7% from the increase in sales, while investment in our US sales and marketing team to support our partners has continued. R&D expense was 8.0% of revenues (2013 H1: 5.9%) with expenditure in this segment being incurred on our Hernia Mesh Fixation device prior to launch, as well as work on a new project to improve our base monomer formulation for our tissue adhesives.

 

OEM

OEM revenues increased by 10.1% to £11.8 million (2013 H1: £10.7 million) and by 12.6% at constant currency. R&D expense was 4.0% of revenues (2013 H1: 3.3%) with spend being incurred on projects to improve our range of foams, with a particular focus on products with antimicrobial properties. These projects are being worked on jointly with the Bulk Materials division.

 

Adjusted operating margin improved by 325 bps to 27.1% (2013 H1: 23.8%) mainly as a result of sales mix.

 

Bulk Materials

Bulk material revenues, excluding intercompany sales, reduced by 14% to £1.9 million (2013 H1: £2.2 million) at reported currency and decreased by 12% at constant currency. The adjusted operating margin including intercompany sales decreased to 9.8% (2013 H1: 20.1%), resulting from the reduced volume of business as well as the change in sales mix.

 

Geographic breakdown of revenues

The geographic breakdown of Group revenues in 2014 is set out in note 5. Overall, less than 40% of revenues are in Euros as the UK companies still invoice in Sterling to most of its European partners, and nearly all sales to the US are invoiced in US Dollars. The Group’s policy is to set up natural hedges where possible and to hedge significant transactional risk. The Group estimates that a 10% movement in the £:US$ or £:Euro exchange rate will impact Sterling revenues by approximately 2% and 4% respectively and, in the absence of any hedging, this would result in an impact on profit of 1.3% and 0.6% respectively.

 

Profit before tax

Profit before tax for the period was 18% higher at £7.1 million (2013 H1: £6.0 million).

 

The Group’s effective rate of tax for the six months was 15.5% (2013 H1: 13.0%). This is reflective of the recognition of previously unrecognised brought forward tax losses in the UK, R&D relief and the continued impact of the phased introduction of the patent box relief scheme. It also reflects the impact of blending profits and losses from different countries and the different tax rates associated with these countries.

 

Profit after tax and earnings per share

Adjusted profit after tax increased by 14% to £6.2 million (2013 H1: £5.4 million), resulting in a 13% increase in adjusted basic earnings per share to 2.97p (2013 H1: 2.63p) and a 13% increase in diluted adjusted earnings per share to 2.92p (2013 H1: 2.59p).

 

Profit after tax increased 15% to £6.0 million (2013 H1: £5.2 million), resulting in a 14% increase in basic earnings per share to 2.88p (2013 H1: 2.53p) and a 13% increase in diluted earnings per share to 2.82p (2013 H1: 2.49p).

 

Dividend per share

The Board intends to pay an interim dividend of 0.22p per share on 31 October 2014 to shareholders on the register on 3 October 2014. This is an increase of 15.8% compared with 2013 H1.

 

Cash Flow and Balance Sheet

 

Table 3 summarises the Group cash flows.

 

Table 3	Six months ended 30 June 2014	Six months ended 30 June 2013
Cash Flow	£’000	£’000
Adjusted operating profit (Table 1)	7,224	6,528
Non-cash items	1,360	1,501
EBITDA6	8,584	8,029
Working capital movement	(1,423)	(2,946)
Operating cash flow	7,161	5,083
Capital expenditure and capitalised R&D	(866)	(1,181)
Net Interest	25	(210)
Tax	(929)	351
Free cash flow	5,391	4,043
Financing	–	(6,764)
Dividends paid	(850)	(712)
Proceeds from share issues	9	266
Exchange losses	364	(55)
Net increase/(decrease) in cash and cash equivalents	4,914	(3,222)

6    EBITDA is earnings before interest, tax, depreciation, intangible asset amortisation and share based payments

 

The Group had an operating cash flow of £7.2 million (2013 H1: £5.1 million) and a conversion of adjusted operating profit into free cash flow of 75% (2013 H1: 62%).

 

Working capital increased by £1.4 million in the period. Inventory increased by £0.3 million to 4.7 months of supply (2013 H1: 4.6 months). Trade receivables increased by £0.3 million with debtor days at 45 (2013 H1: 42 days) in line with the growth of the business. Trade payables reduced by £0.8 million.

 

We have invested £0.6 million in capital equipment and software in the first six months (2013 H1: £0.8 million). The major areas of spend have been in developing our ERP business information system for launch in Etten Leur and in upgrading equipment around the Group. £0.2 million of R&D spend has been capitalised (2013 H1: £0.4 million). No development costs were impaired in the period (2013 H1: £0.3m).

 

Given the repayment of our €25 million term facility in September 2013, finance costs were £nil in the period (H1 2013: £0.2 million). In December 2011, the Group also entered into an £8 million revolving credit facility with HSBC, with a final maturity of 31 July 2015. This facility is for general working capital purposes, and carries an annual interest rate of LIBOR plus a margin of 1.5% to 2.5% depending on the Group’s net debt to EBITDA ratio. At 31 October 2013, this facility was reduced to £4.0 million and was undrawn as at 30 June 2014.

 

Net taxation of £0.8 million has been paid as a result of the fiscal merger of the German group of companies completed in 2012, with payments relating to both 2012 and 2013 being made in the period. Further tax payments of £0.1 million were made in other jurisdictions in which the Group operates.

 

The Group paid its final dividend for the year ended 31 December 2013 of £0.9 million (2013 H1: £0.7 million) on 28 May 2014.

 

The Group had a free cash flow of £5.4 million in the period (2013 H1: £4.0 million), with a net increase in cash equivalents of £4.9 million (2013 H1: £3.2 million decrease).

 

At the end of the period, the Group had net cash⁷ of £10.2 million (2013 H2: net cash⁷ of £5.3 million). The movement in net cash during 2014 H1 is reconciled in Table 4 below:

 

Table 4
Movement in net cash7	£’000
Net cash as at 1 January 2014	5,257
Exchange rate impacts	364
Free cash flow	5,391
Dividends paid	(850)
Proceeds from share issues	9
Net cash as at 30 June 2014	10,171

7    Net cash is defined as cash and cash equivalents plus short term investments less financial liabilities and bank loans

 

The Group’s going concern position is fully described in note 11 and the Group had no borrowings in the period.

 

 

 

CONDENSED CONSOLIDATED INCOME STATEMENT

for the six months ended 30 June 2014

 

		(Unaudited)	(Unaudited)	(Audited)
		Six months ended	Six months ended	Year ended
		30 June 2014	30 June 2013	31 December 2013
	Note	£’000	£’000	£’000
Revenue from continuing operations	5	29,440	27,392	59,499
Cost of sales		(12,600)	(11,748)	(25,231)
Gross profit		16,840	15,644	34,268
Distribution costs		(381)	(324)	(744)
Administration costs		(9,574)	(9,082)	(20,079)
Other income		142	90	281
Profit from operations		7,027	6,328	13,726
Finance income		30	1	1
Finance costs		(3)	(362)	(583)
Profit  before taxation		7,054	5,967	13,144
Income tax	7	(1,090)	(778)	(1,778)
Profit for the period attributable to equity holders of the parent		5,964	5,189	11,366
Earnings per share
Basic	4	2.88p	2.53p	5.52p
Diluted	4	2.82p	2.49p	5.45p
Adjusted diluted	4	2.92p	2.59p	5.64p

 

 

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 

	(Unaudited)	(Unaudited)	(Audited)
	Six months ended	Six months ended	Year ended
	30 June 2014	30 June 2013	31 December 2013
	£’000	£’000	£’000
Profit for the year	5,964	5,189	11,366
Exchange differences on translation of foreign operations	(2,375)	2,439	732
(Loss)/gain arising on cash flow hedges	(79)	(193)	698
Other comprehensive (expense)/income for the period	(2,454)	2,246	1,430
Total comprehensive income for the period attributable to equity holders of the parent	3,510	7,435	12,796

 

 

 

CONDENSED STATEMENT OF FINANCIAL POSITION

 

	(Unaudited)	(Unaudited)	(Audited)
	30 June 2014	30 June 2013	31 December 2013
	£’000	£’000	£’000
Assets
Non-current assets
Acquired intellectual property rights	9,688	10,739	10,256
Software intangibles	1,637	1,468	1,662
Development costs	1,782	1,574	1,702
Goodwill	37,761	40,379	39,278
Property, plant and equipment	16,182	17,472	16,707
Deferred tax assets	1,355	2,446	21,728
Trade and other receivables	18	19	14
	68,423	74,097	71,347
Current assets
Inventories	8,229	8,760	8,042
Trade and other receivables	11,696	10,492	12,158
Current tax assets	63	–	343
Cash and cash equivalents	10,171	5,619	5,257
	30,159	24,871	25,800
Total assets	98,582	98,968	97,147
Liabilities
Current liabilities
Trade and other payables	5,477	4,650	6,298
Current tax liabilities	752	1,144	1,220
Other taxes payable	254	736	260
Other loans	–	8,256	–
Obligations under finance leases	5	4	4
	6,488	14,790	7,782
Non-current liabilities
Trade and other payables	504	546	520
Deferred tax liabilities	2,617	2,873	2,754
Obligations under finance leases	2	5	3
	3,123	3,424	3,277
Total liabilities	9,611	18,214	11,059
Net assets	88,971	80,754	86,088
Equity
Share capital	10,385	10,291	10,343
Share premium	32,517	32,092	32,364
Share-based payments reserve	1,395	1,295	1,326
Investment in own shares	(148)	(77)	(144)
Share-based payments deferred tax reserve	121	74	158
Other reserve	1,531	1,531	1,531
Hedging reserve	572	(240)	651
Translation reserve	(3,042)	1,040	(667)
Retained earnings	45,640	34,748	40,526
Equity attributable to equity holders of the parent	88,971	80,754	86,088